Core Viewpoint - The report provides a verification of Shanghai Sanyou Medical Instrument Co., Ltd.'s pre-investment of self-raised funds into fundraising projects and payment of issuance expenses, confirming compliance with regulatory requirements [1][3]. Group 1: Verification Report - The verification report is intended solely for the purpose of replacing self-raised funds with raised funds for investment projects and issuance expenses [2]. - The management of Sanyou Medical is responsible for providing accurate and complete information in accordance with regulatory guidelines [2]. - The registered accountants conducted the verification in accordance with Chinese CPA standards, ensuring that the information is free from material misstatement [2]. Group 2: Fundraising Overview - The total amount raised from the issuance is RMB 213,999,988.12, with net proceeds after fees amounting to RMB 203,920,127.60 [4][5]. - The company incurred a financial advisory and underwriting fee of RMB 8,702,599.81, which includes VAT [5]. - The net amount raised was verified by an external accounting firm, providing a verification report [4]. Group 3: Investment Project Details - The company plans to use the raised funds primarily for cash consideration in transactions, with 93.85% allocated for this purpose [5]. - As of February 28, 2025, the actual investment amount from self-raised funds into the projects was RMB 57,217,758.05, representing 26.74% of the total planned usage [5][6]. - Specific allocations include RMB 20,084.88 million for cash consideration and RMB 1,315.12 million for intermediary fees and taxes [5]. Group 4: Issuance Expense Payments - The total amount paid from self-raised funds for issuance expenses was RMB 975,324.54 [6]. - Breakdown of issuance expenses includes RMB 821.00 million for financial advisory and underwriting fees, and RMB 101.89 million for audit and verification fees [8].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）第三 届监事会第十七次会议于 2025 年 3 月 26 日以现场会议方式召开。本次会议的通 知于 2025 年 3 月 21 日通过邮件方式送达全体监事。会议应出席监事 3 人，实际 到会监事 3 人，会议由监事会主席马宇立先生主持，本次监事会会议的召集和召 开程序符合有关法律、行政法规、部门规章、规范性文件和 公司章程》的规定， 会议决议合法、有效。 证券代码：688085 证券简称：三友医疗 公告编号：2025-024 上海三友医疗器械股份有限公司 第三届监事会第十七次会议决议公告 二、监事会会议审议情况 议案内容：详见公司同日刊载于上海证券交易所网站 （www.sse.com.cn）的 公司 关于调整部分募投项目内部投资结构及部分募投项目延期的公告》，公告 编号：2025-021。 表决情况：同意 3 票，弃权 0 票，反对 0 票。 （三）审议通过 关于使用募集资金置换预先投入募投 ...

Meeting Overview - The third meeting of the supervisory board of Shanghai Sanyou Medical Instrument Co., Ltd. was held on March 26, 2025, with all three supervisors present [1][2] - The meeting was legally convened and chaired by Mr. Ma Yuli, ensuring compliance with relevant laws and regulations [1] Resolutions Passed - The board approved the proposal regarding the completion of certain fundraising projects, with unanimous support (3 votes in favor) [2] - The board approved the adjustment of the internal investment structure of certain fundraising projects and the postponement of some projects, also with unanimous support (3 votes in favor) [2] - The board approved the use of raised funds to replace self-raised funds that were previously invested in fundraising projects and to cover issuance costs, again with unanimous support (3 votes in favor) [2]

Core Viewpoint - The company announced adjustments to the internal investment structure of certain fundraising projects and the postponement of the "Medical High-Strength Suture and Related Orthopedic Soft Tissue Repair Reconstruction Medical Device Project" to December 31, 2027, without changing the overall direction, total investment amount, functionality, or implementation entity of the fundraising projects [1][6]. Fundraising Basic Situation - The company was approved to publicly issue 51,333,500 shares at a price of RMB 20.96 per share, raising a total of RMB 1,075,950,160, with net proceeds of RMB 978,057,381.28 after deducting issuance costs [1][2]. Fundraising Investment Projects - The total investment for the fundraising projects is RMB 62,200,000, with a committed investment amount of RMB 60,000,000 [3]. Internal Structure Adjustment and Postponement - The internal structure adjustment of the fundraising project involves reducing certain personnel costs and research expenses while increasing construction costs. The total investment remains at RMB 4,500,000 [4][5]. - The project timeline has been extended from March 2025 to December 2027 due to delays in construction, product registration, and other factors [6][7]. Necessity and Feasibility of Project Implementation - The project is necessary due to the limited suppliers in the domestic orthopedic sports medicine field and the need for customized equipment from overseas, which has caused delays [7]. - The company has established a robust research and development system in the field of sports medicine and has already made significant investments in funding, equipment, and personnel, ensuring the feasibility of the project [7][8]. Review Procedures - The adjustments were approved by the company's board and supervisory committee, and the sponsor institution confirmed that the necessary decision-making procedures were followed, with no need for shareholder meeting approval [8][9].

Core Viewpoint - The company has announced the use of raised funds to replace self-raised funds previously invested in projects and to cover issuance expenses, following the approval of its board and supervisory committee [1][5][6]. Fundraising Overview - The company was authorized to raise up to 214 million yuan through the issuance of shares at a price of 16.42 yuan per share, resulting in a total fundraising amount of approximately 214 million yuan, with a net amount of about 204 million yuan after deducting issuance costs [2][3]. - A special account for the management of the raised funds has been established with Shanghai Pudong Development Bank, ensuring regulatory oversight [2]. Investment and Expenditure Details - As of February 28, 2025, the actual investment amount from self-raised funds in the projects was approximately 57.22 million yuan, with 56.24 million yuan allocated for cash consideration and 975,324.54 yuan for issuance expenses [3][5]. - The total amount to be replaced by the raised funds is 57.22 million yuan, which includes both the cash consideration and issuance expenses [5]. Compliance and Approval Process - The decision to use raised funds for replacing self-raised funds was made in accordance with relevant laws and regulations, ensuring that it does not alter the intended use of the raised funds or harm the interests of shareholders [6][7]. - The supervisory committee and independent financial advisor have both provided positive opinions on the matter, confirming that the necessary procedures were followed and that the action aligns with the company's operational needs [6][7].

东方证券股份有限公司 关于上海三友医疗器械股份有限公司 使用募集资金置换预先投入募投项目及已支付发行费用的 自筹资金的核查意见 东方证券股份有限公司（以下简称"独立财务顾问"）作为上海三友医疗器 械股份有限公司（以下简称"三友医疗"、"公司"）发行股份及支付现金购买资 产并募集配套资金暨关联交易的独立财务顾问（主承销商），根据《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板股票上市规则》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对三友医疗本次拟使用募集资金置换预先投入 募投项目及已支付发行费用的自筹资金的情况进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海三友医疗器械股份有限 公司发行股份购买资产并募集配套资金注册的批复》（证监许可〔2025〕109 号）， 公司获准发行股份募集配套资金不超过 21,400 万元。公司本次发行价格为人民 币 16.42 元/股，募集资金总额为人民币 213,999,988.12 元，扣除各项发行费用后 募集资金净额为人民币 203,920,12 ...

东方证券股份有限公司关于 上海三友医疗器械股份有限公司 调整部分募投项目内部投资结构及部分募投项目延期的 核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为上海三友医疗器械股 份有限公司（以下简称"三友医疗"、"公司"）首次公开发行股票并在科创板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创 板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号— —规范运作》等相关法律法规要求，对三友医疗调整"医用高强缝合线及相关 的骨科软组织修复重建医疗器械项目"内部投资结构并延期至 2017 年 12 月 31 日的事项进行了核查，具体情况如下： 一、募集资金基本情况 经上海证券交易所科创板上市委员会 2020 年 1 月 8 日审核同意，并经中国 证券监督管理委员会于 2020 年 3 月 12 日《关于同意上海三友医疗器械股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕402 号），公司获准向社 会公开发行人民币普通股 51,333,500 股，每股面值人民币 1.00 ...

东方证券股份有限公司关于 上海三友医疗器械股份有限公司 部分募投项目结项的核查意见 | 单位：万元 | | --- | | 序号 | 项目名称 | 投资总额 | 拟用募集资金投资额 | | --- | --- | --- | --- | | 1 | 骨科植入物扩产项目 | 24,916.37 | 22,716.37 | | 2 | 骨科产品研发中心建设项目 | 10,775.67 | 10,775.67 | | 3 | 营销网络建设项目 | 7,723.38 | 7,723.38 | | 4 | 补充流动资金 | 18,784.58 | 18,784.58 | | | 合计 | 62,200.00 | 60,000.00 | 注：上表中"骨科植入物扩产项目"已结项，经公司 2022 年第二次临时股东大会审议， 公司使用其节余的部分募集资金 4,500.00 万元新增募投项目"医用高强缝合线及相关的骨 科软组织修复重建医疗器械项目"，该项目计划总投资额为 4,500.00 万元。 东方证券股份有限公司（以下简称"保荐机构"）作为上海三友医疗器械股 份有限公司（以下简称"三友医疗"、"公司"）首次公开发行股票并在 ...

目 录 一、以自筹资金预先投入募投项目及支付发行费用的鉴证报告…第 1—2 页 二、以自筹资金预先投入募投项目及支付发行费用的专项说明…第 3—5 页 天健审〔2025〕6-90 号 上海三友医疗器械股份有限公司全体股东： | 二、附件…………………………………………………………… 第 | 6—10 | 页 | | --- | --- | --- | | （一）本所营业执照复印件 ………………………………………第 | | 6 页 | | （二）本所执业证书复印件 ………………………………………第 | | 7 页 | | （三）本所从事证券服务业务备案完备证明材料 ………………第 | | 8 页 | | （四）签字注册会计师执业证书复印件 ………………… 第 | 9—10 | 页 | 关于上海三友医疗器械股份有限公司 以自筹资金预先投入募投项目及支付发行费用的 鉴证报告 三、注册会计师的责任 我们鉴证了后附的上海三友医疗器械股份有限公司（以下简称三友医疗公司） 管理层编制的《以自筹资金预先投入募投项目及支付发行费用的专项说明》。 一、对报告使用者和使用目的的限定 我们的责任是在实施鉴证工作的基础上对三友医疗公司 ...

上海三友医疗器械股份有限公司 Shanghai Sanyou Medical Co., Ltd. 章 程 二〇二五年三月 | | | | 第一章 | 总 | 则 | | 2 | | --- | --- | --- | --- | --- | | 第二章 | | 经营宗旨和范围 | | 3 | | 第三章 | 股 | 份 | | 3 | | 第一节 | | 股份发行 | | 3 | | 第二节 | | 股份增减和回购 | | 4 | | 第三节 | | 股份转让 | | 6 | | 第四章 | | 股东和股东大会 | | 6 | | 第一节 | | 股 东 | | 7 | | 第二节 | | 股东大会的一般规定 | | 9 | | 第三节 | | 股东大会的召集 | | 12 | | 第四节 | | 股东大会的提案与通知 | | 14 | | 第五节 | | 股东大会的召开 | | 16 | | 第六节 | | 股东大会的表决和决议 | | 19 | | 第五章 | | 董事会 | | 24 | | 第一节 | | 董 事 | | 25 | | 第二节 | | 董事会 | | 28 | | 第三节 | | 董事 ...